Interon Laboratories, Inc. announced a round of funding on February 10, 2023. The transaction will include participation from new investor, Hanall Biopharma Co., Ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
33,300 KRW | -1.19% |
|
+1.37% | -24.83% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.83% | 1.24B | |
+50.68% | 795B | |
+41.96% | 627B | |
-7.27% | 350B | |
+18.50% | 328B | |
+8.92% | 294B | |
+18.02% | 245B | |
+1.27% | 222B | |
+11.95% | 215B | |
+3.61% | 160B |
- Stock Market
- Equities
- A009420 Stock
- News Hanall Biopharma Co., Ltd.
- Interon Laboratories, Inc. announced that it expects to receive funding from Hanall Biopharma Co., Ltd.